Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Depreciation and Depletion (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Depreciation and Depletion for 7 consecutive years, with $5000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion rose 1150.0% to $5000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $178000.0, a 1.71% increase, with the full-year FY2024 number at $200000.0, changed 0.0% from a year prior.
  • Depreciation and Depletion was $5000.0 for Q3 2025 at Whitehawk Therapeutics, down from $16000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $100000.0 in Q4 2024 to a low of $400.0 in Q3 2024.
  • A 4-year average of $41231.7 and a median of $43500.0 in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: plummeted 99.09% in 2024, then surged 1150.0% in 2025.
  • Whitehawk Therapeutics' Depreciation and Depletion stood at $16780.0 in 2021, then soared by 346.96% to $75000.0 in 2023, then skyrocketed by 33.33% to $100000.0 in 2024, then tumbled by 95.0% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Depreciation and Depletion are $5000.0 (Q3 2025), $16000.0 (Q2 2025), and $57000.0 (Q1 2025).